188 related articles for article (PubMed ID: 24788596)
1. Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines.
Ling S; Feng T; Ke Q; Fan N; Li L; Li Z; Dong C; Wang C; Xu F; Li Y; Wang L
Oncol Rep; 2014 Jun; 31(6):2611-8. PubMed ID: 24788596
[TBL] [Abstract][Full Text] [Related]
2. Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.
Ling S; Xie H; Yang F; Shan Q; Dai H; Zhuo J; Wei X; Song P; Zhou L; Xu X; Zheng S
J Hematol Oncol; 2017 Feb; 10(1):59. PubMed ID: 28241849
[TBL] [Abstract][Full Text] [Related]
3. Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro.
Wu WR; Zhang R; Shi XD; Zhu MS; Xu LB; Zeng H; Liu C
Oncol Rep; 2014 Jun; 31(6):2515-24. PubMed ID: 24700253
[TBL] [Abstract][Full Text] [Related]
4. Metformin enhances cisplatin induced inhibition of cholangiocarcinoma cells via AMPK-mTOR pathway.
Wandee J; Prawan A; Senggunprai L; Kongpetch S; Tusskorn O; Kukongviriyapan V
Life Sci; 2018 Aug; 207():172-183. PubMed ID: 29847773
[TBL] [Abstract][Full Text] [Related]
5. Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
Yang SH; Lin HY; Chang VH; Chen CC; Liu YR; Wang J; Zhang K; Jiang X; Yen Y
Oncotarget; 2015 Sep; 6(27):23857-73. PubMed ID: 26160843
[TBL] [Abstract][Full Text] [Related]
6. Benefits of Metformin Use for Cholangiocarcinoma.
Kaewpitoon SJ; Loyd RA; Rujirakul R; Panpimanmas S; Matrakool L; Tongtawee T; Kootanavanichpong N; Kompor P; Chavengkun W; Kujapun J; Norkaew J; Ponphimai S; Padchasuwan N; Pholsripradit P; Eksanti T; Phatisena T; Kaewpitoon N
Asian Pac J Cancer Prev; 2015; 16(18):8079-83. PubMed ID: 26745042
[TBL] [Abstract][Full Text] [Related]
7. Metformin Exerts Antiproliferative and Anti-metastatic Effects Against Cholangiocarcinoma Cells by Targeting STAT3 and NF-ĸB.
Saengboonmee C; Seubwai W; Cha'on U; Sawanyawisuth K; Wongkham S; Wongkham C
Anticancer Res; 2017 Jan; 37(1):115-123. PubMed ID: 28011481
[TBL] [Abstract][Full Text] [Related]
8. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.
Zhang S; Song X; Cao D; Xu Z; Fan B; Che L; Hu J; Chen B; Dong M; Pilo MG; Cigliano A; Evert K; Ribback S; Dombrowski F; Pascale RM; Cossu A; Vidili G; Porcu A; Simile MM; Pes GM; Giannelli G; Gordan J; Wei L; Evert M; Cong W; Calvisi DF; Chen X
J Hepatol; 2017 Dec; 67(6):1194-1203. PubMed ID: 28733220
[TBL] [Abstract][Full Text] [Related]
9. TAZ regulates cell proliferation and sensitivity to vitamin D3 in intrahepatic cholangiocarcinoma.
Xiao H; Tong R; Yang B; Lv Z; Du C; Peng C; Ding C; Cheng S; Zhou L; Xie H; Wu J; Zheng S
Cancer Lett; 2016 Oct; 381(2):370-9. PubMed ID: 27554639
[TBL] [Abstract][Full Text] [Related]
10. Hydroxytyrosol inhibits cholangiocarcinoma tumor growth: an in vivo and in vitro study.
Li S; Han Z; Ma Y; Song R; Pei T; Zheng T; Wang J; Xu D; Fang X; Jiang H; Liu L
Oncol Rep; 2014 Jan; 31(1):145-52. PubMed ID: 24247752
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of active autophagy induces apoptosis and increases chemosensitivity in cholangiocarcinoma.
Hou YJ; Dong LW; Tan YX; Yang GZ; Pan YF; Li Z; Tang L; Wang M; Wang Q; Wang HY
Lab Invest; 2011 Aug; 91(8):1146-57. PubMed ID: 21647092
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin inhibits both motility through down-regulation of p-STAT3 (S727) by disrupting the mTORC2 assembly and peritoneal dissemination in sarcomatoid cholangiocarcinoma.
Hong SM; Park CW; Cha HJ; Kwon JH; Yun YS; Lee NG; Kim DG; Nam HG; Choi KY
Clin Exp Metastasis; 2013 Feb; 30(2):177-87. PubMed ID: 22875246
[TBL] [Abstract][Full Text] [Related]
13. Metformin enhances radiation response of ECa109 cells through activation of ATM and AMPK.
Feng T; Li L; Ling S; Fan N; Fang M; Zhang H; Fang X; Lan W; Hou Z; Meng Q; Jin D; Xu F; Li Y
Biomed Pharmacother; 2015 Feb; 69():260-6. PubMed ID: 25661368
[TBL] [Abstract][Full Text] [Related]
14. The dual effects of delta(9)-tetrahydrocannabinol on cholangiocarcinoma cells: anti-invasion activity at low concentration and apoptosis induction at high concentration.
Leelawat S; Leelawat K; Narong S; Matangkasombut O
Cancer Invest; 2010 May; 28(4):357-63. PubMed ID: 19916793
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II enhances epithelial-to-mesenchymal transition through the interaction between activated hepatic stellate cells and the stromal cell-derived factor-1/CXCR4 axis in intrahepatic cholangiocarcinoma.
Okamoto K; Tajima H; Nakanuma S; Sakai S; Makino I; Kinoshita J; Hayashi H; Nakamura K; Oyama K; Nakagawara H; Fujita H; Takamura H; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Harada S; Wakayama T; Iseki S; Ohta T
Int J Oncol; 2012 Aug; 41(2):573-82. PubMed ID: 22664794
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal stem cells promote chemoresistance by activating autophagy in intrahepatic cholangiocarcinoma.
Gan L; Shen H; Li X; Han Z; Jing Y; Yang X; Wu M; Xia Y
Oncol Rep; 2021 Jan; 45(1):107-118. PubMed ID: 33155663
[TBL] [Abstract][Full Text] [Related]
17. RA190, a Proteasome Subunit ADRM1 Inhibitor, Suppresses Intrahepatic Cholangiocarcinoma by Inducing NF-KB-Mediated Cell Apoptosis.
Yu GY; Wang X; Zheng SS; Gao XM; Jia QA; Zhu WW; Lu L; Jia HL; Chen JH; Dong QZ; Lu M; Qin LX
Cell Physiol Biochem; 2018; 47(3):1152-1166. PubMed ID: 29913454
[TBL] [Abstract][Full Text] [Related]
18. The antidiabetic drug metformin inhibits uterine leiomyoma cell proliferation via an AMP-activated protein kinase signaling pathway.
Li B; Takeda T; Tsuiji K; Kondo A; Kitamura M; Wong TF; Yaegashi N
Gynecol Endocrinol; 2013 Jan; 29(1):87-90. PubMed ID: 22835064
[TBL] [Abstract][Full Text] [Related]
19. Triptolide inhibits intrahepatic cholangiocarcinoma growth by suppressing glycolysis via the AKT/mTOR pathway.
Li L; Wang C; Qiu Z; Deng D; Chen X; Wang Q; Meng Y; Zhang B; Zheng G; Hu J
Phytomedicine; 2023 Jan; 109():154575. PubMed ID: 36610163
[TBL] [Abstract][Full Text] [Related]
20. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase.
Lin Y; Cai Q; Chen Y; Shi T; Liu W; Mao L; Deng B; Ying Z; Gao Y; Luo H; Yang X; Huang X; Shi Y; He R
Hepatology; 2022 Jan; 75(1):28-42. PubMed ID: 34387870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
